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Introduction
Cardiovascular diseases are the primary cause of mortal-
ity and morbidity worldwide (1). In parallel with the increase in 
the number of cardiovascular diseases, the developments in 
new invasive and noninvasive techniques that evaluate the se-
verity of cardiovascular diseases still continue. Left ventricular 
end-diastolic pressure (LVEDP) measurement during left heart 
catheterization is an invasive method used as an indicator of left 
ventricular function. Several clinical disturbances that can affect 
left ventricular performance may cause elevated LVEDPs. How-
ever, since this technique requires arterial puncture and left heart 
catheterization, noninvasive alternative methods that can provide 
the information about LVEDP are needed.
Resistin is a cysteine-rich polypeptide and a member of a 
family known as resistin-like molecules. It was first discovered in 
rodents for its role in insulin resistance and obesity (2). Rodent 
resistin is mostly secreted from adipose tissue (3). In contrast to 
rodents, human resistin is mostly expressed from inflammatory 
cells (4, 5). Human resistin is 59% similar to rodent insulin in terms 
of amino acid level. Several studies have indicated resistin’s re-
lationship with health issues such as insulin resistance, obesity, 
nonalcoholic liver diseases, rheumatological diseases, malignan-
cies, asthma, inflammatory bowel diseases, and chronic kidney 
diseases in humans (2, 6-10). There is also a relationship between 
the elevated levels of resistin and inflammatory processes and 
atherosclerosis in humans (11, 12). Resistin levels also increase 
as the symptoms of heart failure worsen (13). Some studies show 
that the high levels of resistin predict the development of heart 
failure (14, 15). Higher resistin levels are measured in acute coro-
nary syndrome patients (16-18). Other studies on coronary angiog-
raphy found resistin levels to be increased according to the num-
ber of coronary arteries with ≥50% stenosis (19, 20). In contrast, 
other publications show no relationship between resistin levels 
and coronary artery diseases (CAD) (21-24). 
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Some studies suggest that resistin levels increase as heart 
failure symptoms worsen and that hypervolemia in these patients 
is symptomatic (13). Since LVEDP increases with hypervolemia, 
we hypothesized that resistin level would be higher as LVEDP in-
creases. In our present study, we examined whether the serum 
levels of resistin are associated with LVEDP and whether we can 
noninvasively predict LVEDP. We also addressed the relationship 
between resistin levels and the severity of CAD, CIMT, and the 
echocardiographic parameters of diastolic heart failure. 
Methods
Study participants
The study was reviewed and approved by the Ethics Commit-
tee of Başkent University, and informed consent was obtained 
from each subject. Serum resistin levels were measured in 128 
subjects who were referred to the Invasive Laboratory for coro-
nary angiography between February 2014 and September 2014. 
Coronary angiography was performed in 63 (49.6%) patients due 
to typical angina pectoris symptoms, 48 (37.8%) patients due to 
positive stress tests, and 17 (12.6%) patients due to other rea-
sons, including ischemia on ECG and left ventricular systolic 
dysfunction on echocardiography. Hypervolemic patients, tachy-
cardic patients (heart rate >100 bpm), patients with acute coro-
nary syndrome, serious valve regurgitation, stenosis, previous 
diagnosis of asthma, chronic kidney diseases, chronic inflam-
matory diseases, or malignancy, obese patients, and diabetic 
patients were excluded from this study. All study participants 
belonged to class 1 according to New York Heart Association 
classification. 
Evaluated parameters
Blood samples for serum resistin levels were obtained after 
the admission of the patients to the Invasive Laboratory and just 
before the coronary angiography procedure. The samples were 
then centrifuged at 3,500×g or 15 min, and the serum obtained 
was stored at −20°C until analysis. The serum resistin concen-
tration was measured using enzyme-linked immunosorbent as-
say (ELISA; eBioscience, Vienna, Austria).
Clinical data were obtained from patient interviews and hos-
pital medical records. Hypertensive patients were defined as 
systolic blood pressure ≥140 mm Hg, diastolic blood pressure 
≥90 mm Hg, or as those using antihypertensive medication for 
the study purpose according to the 2013 guidelines of the Euro-
pean Society of Hypertension and the European Society of Car-
diology task force for the management of arterial hypertension. 
Hyperlipidemia was defined LDL >130 mg/dL, triglyceride > 200 
mg/dL, and HDL <50 mg/dL for females and <40 mg/dL for males. 
Coronary angiography was performed using a modified Selding-
er technique through a radial or femoral approach. LVEDP was 
measured before coronary angiography and before the injection 
of contrast material. Severe CAD was defined as ≥50% stenosis 
in a minimum of one of the major coronary arteries. The severity 
of CAD was evaluated by the Gensini score. A two-dimensional 
echocardiography was performed after hospitalization and be-
fore the CAG procedure. Ejection fraction (EF), the ratio of peak 
velocity flow in early diastole to the peak velocity flow in the late 
diastole (E/A), the ratio of E to the early diastolic mitral annular 
velocity (E/e’), mitral deceleration time (MDT), left atrium volume 
index (LAVi), mitral propagation time (Vp), E/Vp, and isovolemic 
relaxation time (IVRT) were also examined. CIMT was measured 
after the echocardiography with a 4.5–12.0 MHz linear transducer.
Statistical methods
Data are presented as mean ± standard deviation and as 
proportions for categorical variables. The t-test and chi-square 
test was used for the comparisons of continuous and categorical 
variables, respectively. The data distribution for normality was 
tested by the Shapiro-Wilk test, and the homogeneity of group 
variances were tested by the Levene test. For the parameters 
that were not normally distributed, the Mann-Whitney U-test 
was used. ANOVA model was used for comparisons across >2 
groups. The Spearman correlation test was used for correlation 
analysis. P<0.05 was considered to be statistically significant. 
The data were analyzed using SPSS 20.0 (IBM SPSS Ver. 20.0; 
IBM Corp, Armonk NY, USA).
Results
A total of 445 patients who applied to the Invasive Laboratory 
for coronary angiography between February 2014 and Septem-
ber 2014 were evaluated in this study. Among these patients, 317 
of them were excluded because they did not meet the inclusion 
criteria. For this study, 128 patients were finally enrolled. The 
mean age of the study population was 59±12.5 years; 66.4% were 
male and 33.6% were female. The baseline characteristics of the 
study population are shown in Table 1.
After CAG, 60 patients (46.9%) had severe CAD and were clas-
sified as the severe CAD group, whereas 68 patients (53.1%) did 
not have severe CAD and were classified as the control group.
The proportion of male population was significantly higher 
in the CAD group than that in the control group. Additionally, the 
mean age and serum creatinine levels were significantly higher 
in the CAD group than those in the control group. EF was signifi-
cantly higher in the control patients when compared with that 
in the CAD group (p=0.003). However, there was no difference in 
the incidences of hypertension, dyslipidemia, stroke, peripheral 
vascular disease, smoking, and family history of CAD. The mean 
fasting blood sugar, total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol, and triglycer-
ide levels were also similar between the groups. LVEDP results 
were also similar (Table 2). 
When the drug use of the study groups was examined, a sta-
tistically significant difference was found in the use of acetylsal-
icylic acid (p=0.006), clopidogrel (p=0.005), angiotensin convert-
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ing enzyme inhibitor or angiotensin receptor blocker (p=0.004), 
beta blocker (p=0.032), calcium channel blocker (p=0.004), nitrate 
(p=0.027), and statin (p=0.001) between the groups (Table 3).
The serum resistin levels were 2626.2±1513.3 pg/mL in the 
CAD group and 3031.9±1638.6 pg/mL in the control group, and the 
difference was not statistically significant (p=0.154). The mean 
LVEDPs were also similar for the patients with and without se-
vere CAD (p=0.480; Fig. 1).
The resistin levels were also evaluated between the patients 
with normal coronary arteries (n=22) and the patients with minimal 
CAD (n=46) or severe CAD (n=60). There was also no significant 
difference in the resistin levels among these three groups (Fig. 2).
A comparison of the resistin levels of reduced EF (EF <50%) 
patients (n=30) and preserved EF (EF ≥50%) patients (n=98) also 
showed no significant difference (p=0.531). In the subgroup of 
patients with preserved EF (n=98), no significant difference was 
found in the resistin levels of the patients with severe CAD or 
those of the control group (p=0.257). LVEDP was 18.9±8.0 in the 
preserved EF group and 18.1±6.2 in the reduced EF group, and the 
results were statistically similar between the groups (p=0.649).
The patients with diastolic dysfunction were further classi-
fied as grade 1 (n=53), grade 2 (n=19), and grade 3 (n=2) groups. 
The serum resistin levels were similar among all diastolic dys-
function groups (p=0.383). A pairwise comparison of the resistin 
levels of these three groups did not show any significant differ-
ence between the resistin levels as shown in Figure 3.
In the complete study population, the resistin levels were not 
significantly correlated to LVEDP (r=−0.045, p=0.627). Further-
more, there was no correlation between the resistin level and 
age (r=−0.056, p=0.535), EF (r=0.110, p=0.228), and the Gensini 
score (r=−0.091, p=0.328). 
The resistin levels were compared among the subgroups of 
drug use, including acetylsalicylic acid, clopidogrel, angioten-
sin converting enzyme inhibitor or angiotensin receptor blocker, 
beta blocker, calcium channel blocker, nitrate, and statins. There 
were no significant differences among these subgroups (p>0.05 
for all comparisons). 
The Spearman correlation analysis was applied to the echo-
cardiographic diastolic dysfunction parameters and resistin 
Figure 1. (a) Box-plot graph of patients groups and resistin levels. (b) 
Box-plot graph of patient groups and left ventricular end-diastolic 
pressure
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Table 1. Baseline characteristics of the study population
Age, years 59.0±12.5
Gender, Male/Female 85/43
Hypertension, % 65.5
Hyperlipidemia, % 54.3
Stroke, % 1.6
Peripheral vascular disease, % 1.6
Smoking, % 35.6
Family history of CAD, % 59.8
Ejection fraction, % 52.6±9.7
LVEDP, mm Hg 18.6±7.5
GFR, mg/dL 58.6±7.8 
Blood examination 
 FBS mg/dL 97.6±9.9
 Creatinine, mg/dL 0.9±0.2
 HDL-C, mg/dL 46.7±18.4
 LDL-C, mg/dL 128.7±56.0
 TG, mg/dL 152.4±87.8
 Hb, g/dL 14.5±1.5
 WBC count 7800±1900
Platelet count 255400±73200
Resistin, pg/mL 2845.1±1588.9
CAD - coronary artery disease; GFR - glomerular filtration rate; FBS - fasting blood 
sugar; HDL-C - high-density lipoprotein cholesterol; Hb - hemoglobin; LDL-C - low-
density lipoprotein cholesterol; LVEDP - left ventricular end-diastolic pressure; TG - 
triglyceride; WBC - white blood cell
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levels, and no relationship was found between the resistin levels 
and E/e’ (r=−0.072, p=0.468), e’ (r=0.037, p=0.738), E/A (r=0.018, 
p=0.847), MDT (r=0.022, p=0.828), LAVi (r=−0.087, p=0.432), Vp (r= 
.102, p=0.391), E/Vp (r=−171, p=0.158), and IVRT (r=−0.017, p=0.866).
The carotid intima-media thickness was measured in 86 pa-
tients, and no relationship was found between the resistin level 
and CIMT (r=0.082, p=0.457). There were statistically significant 
correlations between the resistin level and CIMT in hypertensive 
patients (n=55) and the patients with severe CAD (n=41; r=0.282, 
p=0.041 and r=0.485, p=0.002, respectively).
There was a statistically significant difference between the 
severe CAD and control groups with respect to CIMT (0.99±0.34 
mm for patients with severe CAD and 0.7±0.19 mm for those with-
out severe CAD; p=0.000).
Discussion
Our study showed that resistin has no relationship with 
LVEDP, CAD severity, CIMT, and the echocardiographic diastolic 
dysfunction parameters. 
Table 2. Study group characteristics and laboratory 
parameters
 CAD group Control group P-value
 (n=60) (n=68)
Age, years 61.5±12.6 56.7±12.0 0.033
Male, % 48 (80.0) 37 (54.4) 0.002
HT, % 42 (71.2) 41 (60.3) 0.198
HL, % 35 (59.3) 34 (50.0) 0.293
Stroke, % 2 (3.4) 0 (0) 0.126
PVD, % 2 (3.4) 0 (0) 0.126
Smoking, % 17 (31.5) 24 (38.7) 0.417
Family history of CAD, % 26 (60.5) 35 (59.3) 0.907
Ejection fraction, % 49.8±10.9 55.1±8.0 0.003
LVEDP, mm Hg 19.1±7.9 18.1±7.2 0.480
FBS, mg/dL 99.7±10.4 96.0±9.3 0.061
Creatinine, mg/dL 0.9±0.2 0.8±0.1 0.006
HDL-C, mg/dL 43.6±16.6 49.3±19.8 0.228
LDL-C, mg/dL 127.9±63.8 129.5±48.6 0.880
TG, mg/dL 151.7±75.6 153.1±99.2 0.936
Resistin, pg/mL 2626.2±1513.3 3031.9±1638.6 0.154
CAD - coronary artery disease; FBS - fasting blood sugar; HDL-C - high-density 
lipoprotein cholesterol; HL -hyperlipidemia; HT - hypertension; LDL-C - low-density 
lipoprotein cholesterol; LVEDP - left ventricular end-diastolic pressure; PVD - peripheral 
vascular disease; TG - triglyceride
Table 3. Drug use in study groups 
Drugs Control CAD P
 group group value
 (n=68) (n=60)
Acetylsalicylic acid n (%) 22 (32.4%) 33 (56.9%) 0.006
Clopidogrel n (%)  3 (4.4%) 12 (20.7%) 0.005
ACEI/ARB n (%)  25 (36.8%) 37 (62.7%) 0.004
Beta blocker n (%)  24 (35.3%) 32 (54.2%) 0.032
Calcium channel blocker n (%) 4 (5.9%) 14 (23.7%) 0.004
Alpha blocker n (%) 0 (0%) 1 (1.7%) 0.285
Trimetazidine n (%) 3 (4.4%) 5 (8.5%) 0.347
Nitrates n (%) 2 (2.9%) 8 (13.6%) 0.027
Spironolactone n (%) 2 (3.0%) 1 (1.7%) 0.635
Statin n (%) 13 (19.1%) 28 (47.5%) 0.001
Furosemide n (%) 1 (1.5%) 4 (6.8%) 0.125
ACEI - angiotensin converting enzyme inhibitor; ARB - angiotensin receptor blocker; 
CAD - coronary artery disease
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Figure 2. Relationship between the study groups and resistin levels
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Resistin is a peptide implicated in cardiovascular diseases in 
many studies (25). LVEDP is a parameter that can be measured 
by left heart catheterization, indicating pressure and volume 
load conditions. It can also provide valuable data on the relation-
ship of systolic performance of the left ventricle and diastolic 
pressure volume (26). This study aimed to determine whether 
LVEDP, an invasively measured parameter, could be predicted 
by resistin level, a biomarker that has previously been shown to 
increase during hypervolemia or symptomatic heart failure. We 
excluded the patients with infection, malignancy, diabetes, and 
acute coronary syndrome because resistin is also shown to be 
an inflammatory mediator (9, 11, 19). The relationship between 
resistin and heart failure has been investigated in many previous 
studies (13, 27). Takeishi et al. (13) compared the resistin levels 
in symptomatic heart failure patients and control group, which 
showed that resistin levels increased along with NYHA class. 
Baldasseroni et al. (27) compared the resistin levels of asymp-
tomatic preserved EF, asymptomatic reduced LVEF, and symp-
tomatic reduced LVEF patients. Only in the symptomatic reduced 
LVEF patients, the levels were higher. The resistin levels of the 
asymptomatic reduced LVEF and preserved LVEF patients were 
statistically similar. This finding suggest that resistin levels only 
increase in symptomatic, hypervolemic patients and that EF has 
no effect on resistin levels. Our results suggest no statistically 
significant relationship in terms of the resistin levels between 
the reduced LVEF and preserved LVEF groups. As mentioned ear-
lier, the hypervolemic and symptomatic patients were excluded 
in our study, so this finding is consistent with the study of Baldas-
seroni et al. (27). In our study, no significant correlation between 
the resistin levels and LVEDP was observed. The exclusion crite-
ria for this study include all causes that increase LVEDP, except 
for heart failure. Our goal in this study was to understand LVEDP 
using only resistin, thus avoiding an invasive examination. As 
explained before, previous studies found increased resistin lev-
els in hypervolemic patients, so we expected to find increased 
levels of resistin along with higher LVEDP values. Contrary to our 
prediction, there was no significant relationship between LVEDP 
and resistin levels.
EF was higher in the control group compared with that in 
the severe CAD patients. However, in these patients, the LVEDP 
results were statistically similar. Left ventricular end-diastolic 
pressure is expected to be higher when left ventricular volume 
load is increased; hence, during hypervolemic conditions and 
heart failure, LVEDP is expected to be higher. However, in our 
study, although the severe CAD patients had lower LVEF, the 
LVEDP values were statistically similar. This may be caused by 
the fact that our patients were all normovolemic and that the 
number of reduced EF patients were lower.
There are some studies that show positive correlation be-
tween resistin levels (16–20) and the severity of CAD and few 
other studies that report that there is no correlation between 
them (21–24). In our study, there was no statistically significant 
relationship between resistin and CAD. When the articles with 
statistically significant results were examined, it was found that 
the resistin levels mostly increased in the cases of acute coro-
nary syndromes and that there was no significant increase in 
the stable angina pectoris cases (16, 18, 20, 22). In some stud-
ies, while there was a relationship between resistin and CAD at 
the beginning, when the inflammatory parameters such as CRP 
included in the study, it was found that the relationship was origi-
nated from inflammation rather than CAD; after adjustment, the 
association was no longer significant (23, 28). The strong rela-
tionship between CRP and resistin has been determined repeat-
edly in many CAD related studies (19–21). In our study, inflam-
matory conditions such as acute coronary syndrome, infection, 
chronic inflammatory diseases, and malignancy were excluded. 
Given this situation, it is not surprising that there is no significant 
relationship between resistin and CAD.
In our study, a significant relationship between the resistin 
levels and CIMT was found in hypertensive patients. Shin et al. 
(29) also reviewed CIMT and resistin levels in 307 hypertensive 
patients, and a similar relationship was found. Several studies 
demonstrated a relationship among atherosclerosis, vascular 
inflammation, and resistin (11, 12). Further, resistin expression is 
increased in human carotid artery samples (30). This increased 
release in carotid arteries may be the cause of the relationship 
between CIMT and resistin levels in our study, or this finding may 
be coincidental. To clarify why resistin levels are not affected 
by CAD severity but are affected by CIMT, more detailed studies 
including coroner and carotid arteries should be designed.
Study limitations
A limitation to our work is that the size of the reduced EF pa-
tient was low. Additionally, it would be better to simultaneously 
monitor resistin and CRP levels; however, since we excluded all 
the inflammatory diseases and CRP increased situations, we be-
lieve that this is not a major limitation to our study.
Conclusion
In conclusion, resistin seems to be an inflammatory bio-
marker with no direct relationship with LVEDP, CAD, systolic, and 
diastolic dysfunction. Only in hypertensive patients, there is a 
borderline relationship between resistin and CIMT, which may 
be caused by atherosclerotic processes. 
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